Live feed16:05:00·6dPRReleasevia QuantisnowBBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026ByQuantisnow·Wall Street's wire, on your screen.BBOT· BridgeBio Oncology Therapeutics Inc.Health Care
